BaF3 cancer kinase target engineered cell library for preclinical drug development and tumor precision medicine. Provides standardized cell models to support oncology research, antibody-drug conjugate evaluation, and immunotherapy screening applications.
Manufactured by
China
PreceDo Pharmaceuticals is a state-controlled high-tech enterprise established in 2015, affiliated with Chinese Academy of Sciences Hefei Institute. The company specializes in cell engineering technology, featuring proprietary HDS tumor precision medication technology, Ba/F3 cancer kinase target engineered cell library, and an approved renewable cancer primary cell biobank for anti-tumor drug development and clinical precision treatment.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
Bencos Healthcare Solutions Pvt Ltd
India · 1 relevant product
Fortis Life Sciences LLC
United States · 1 relevant product
Clear Labs, Inc
United States · 1 relevant product
10 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →5 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
3 of 14 closest product alternatives
Bencos Healthcare Solutions Pvt Ltd · India
Platform-independent NGS library preparation kits for custom genomic panel design. Enables next-generation sequencing workflows with room-temperature stable reagents that simplify sample preprocessing and reduce pre-analytical variables in molecular diagnostics.
Fortis Life Sciences LLC · United States
First-in-class peripheral NK cell-derived VHH library designed for identifying differentiated binders for NK-associated targets. Supports CAR-NK research, target discovery, and advanced screening workflows.
Clear Labs, Inc · United States
An automated next-generation sequencing (NGS) platform designed to streamline oncology sequencing workflows. Clear Dx® automates key steps in library preparation and sequencing setup, reducing hands-on time while improving consistency and reproducibility across complex genomic assays. The platform supports a wide range of oncology research workflows, including targeted sequencing of solid tumor samples, liquid biopsy applications, and fusion detection assays, and integrates with secondary and tertiary bioinformatics platforms for variant analysis, interpretation, and results reporting.
11 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products